MAPT and Alzheimer disease: The aim of this study was to investigate the CSF levels of MCH and HCRT-1 in patients with AD and HS and the potentially causal relationship between these polypeptides and CSF levels of the AD marker total Tau (T-tau), hyperphosphorylated tau (P-tau) and Aβ42, cognitive performance and behavioral symptoms in AD.